What's in Nicox Ophthalmics, Inc.'s pipeline?

Nicox Ophthalmics, Inc. has 4 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Nicox Ophthalmics, Inc.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/nicox-ophthalmics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Nicox Ophthalmics, Inc. — Portfolio Competitive Intelligence Brief

Nicox Ophthalmics, Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
NCX 470 0.1%	NCX 470 0.1%	phase 3	Nitric oxide-donating prostaglandin F analog	Prostaglandin F receptor (FP receptor); nitric oxide pathway	Ophthalmology
AC-170 Vehicle	AC-170 Vehicle	phase 3			Ophthalmology

Therapeutic area mix

Ophthalmology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Nicox Ophthalmics, Inc.:

Cite this brief

Drug Landscape (2026). Nicox Ophthalmics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nicox-ophthalmics-inc. Accessed 2026-05-16.